Preventing relapse after CAR T-cell therapy (WISH) — Chimeric antigen receptor T-cell therapy is revolutionizing the treatment of certain blood cancers. CAR T-cell therapy uses genetically enhanced versions of a patient’s own cancer-fighting T-cells, offering a personalized approach that targets and destroys tumor cells. However, one significant challenge is a high rate of relapse. Now, a novel approach is helping to keep patients’ cancer-free for longer. News 8s Brittany Noble has details in Monday’s Health Spotlight. This story was created from a script aired on WISH-TV. Health Spotlight is presented by Community Health Network.